Skip to main content
OpenTrials
Completed

NCT Number: NCT00503139

Study Evaluating the Safety and Efficacy of Enbrel (Etanercept) in Japan

The special use-results surveillance is conducted in patients who have never been treated with Enbrel and in whom its long-term therapy may be instituted in the actual setting of use after marketing with the following objectives: 1. To examine the safety of long-term use of Enbrel including the occurrence of malignant tumors. 2. To confirm the efficacy of Enbrel in the long-term use.

Completed

Looking for future studies?

Notify Me

Key information

Age range

10 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hokkaido University Hospital

Sapporo, 060-8638, Japan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Inclusion criteria

Patients with rheumatoid arthritis (RA) who fulfill all of the following

  • Patients who are refractory to the treatment.
  • Patients who have never been treated with Enbrel and in whom its long-term therapy may be instituted.
  • Patients without a history of or concurrent malignant tumors.

Exclusion criteria

Treatment and study plan

Enbrel (Etanercept)

Drug

Enbrel 10 to 25 mg twice a week subcutaneous injection

Primary outcomes

  1. Number of Participants in Safety Analysis Population of Etanercept

    Time frame: 3 years

  2. Number of Participants With Treatment Related Adverse Events of Etanercept

    Time frame: 3 years

    Adverse events are all unfavorable events, including clinically problematic abnormal changes in laboratory test values, which develop in participants after the administration of Etanercept, irrespective of causal relationship to Etanercept. The causal relationship between an adverse event and Etanercept was evaluated by the sponsor.

  3. Number of Participants With Serious Treatment Related Adverse Events of Etanercept

    Time frame: 3 years

    Serious treatment-related adverse events are defined as any events that lead to death, life-threatening, hospitalization or prolonged hospitalization, a permanent or remarkable disorder/dysfunction, congenital anomaly/congenital deficiency, or other medically significant events or disorder.

  4. Number of Participants With Unlisted Treatment Related Adverse Events of Etanercept

    Time frame: 3 years

    Adverse events are all unfavorable events, including clinically problematic abnormal changes in laboratory test values, which develop in participants after the administration of Etanercept, irrespective of causal relationship to Etanercept. The causal relationship between an adverse event and Etanercept was evaluated by the sponsor. Unlisted treatment related adverse events were confirmed with listed adverse drug reactions specified in Japanese package insert.

  5. European League Against Rheumatism (EULAR) Disease Activity Score (DAS) 28 Improvement (4/Erythrocyte Sedimentation Rate: ESR)

    Time frame: 2 years

    DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hour) and PtGA of disease activity (participant rated arthritis activity assessment). Total score range: 0-9.4, higher score=more disease activity. DAS28-4 (ESR) <= 3.2 implied low disease activity and >3.2 to 5.1 implied moderate to high disease activity, and DAS28-4 (ESR) <2.6 = remission.

Secondary outcomes

  1. Modified Health Assessment Questionnaire (mHAQ) Score

    Time frame: 2 years

    Modified Health Assessment Questionnaire-(mHAQ): participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

  2. Visual Analog Fatigue Scale (VAFS)

    Time frame: 2 years

    Participants assessed their fatigue using a 0 - 100 mm VAS, where 0 mm = no fatigue and 100 mm = worst possible fatigue.

  3. European League Against Rheumatism (EULAR) Disease Activity Score (DAS) 28 Improvement (3/Erythrocyte Sedimentation Rate: ESR)

    Time frame: 2 years

    DAS28-3 (ESR) was calculated from swollen joint count (SJC) and tender joint count (TJC) using 28 joints count and ESR (mm/hour). Total score range: 0-9.4, higher score=more disease activity. DAS28-3 (ESR) <= 3.2 implied low disease activity and >3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (ESR) <2.6 = remission.

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

Enbrel Special Use Result Surveillance

Important dates

Study start
2007
Primary completion
2013
Study completion
2013
First posted
Jul 18, 2007
Registry last updated
Feb 28, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.